Search





Search





Markets
/
Stocks
/
nasdaq-derm
/

Journey Medical Corp

DERM

Add to Watchlist

6.250USD

-0.080-1.26%

Close 05/18, 16:00（ET）Quotes delayed by 15 min

134.59MMarket Cap

LossP/E TTM



Journey Medical Corp

6.250

-0.080-1.26%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Journey Medical Corp

Currency: USD Updated: 2026-05-18

Key Insights

Journey Medical Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 39 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.50.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Journey Medical Corp's Score

Industry at a Glance

Industry Ranking

39 / 155

Overall Ranking

107 / 4479

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Journey Medical Corp Highlights

StrengthsRisks

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Growing

The company is in a growing phase, with the latest annual income totaling USD 61.86M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 61.86M.

Fairly Valued

The company’s latest PE is -17.05, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 12.08M shares, increasing 18.49% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 11.34K shares of this stock.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

13.500

Target Price

+113.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-18

The current financial score of Journey Medical Corp is 8.59, ranking 44 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.59

Change



Financials

7.12

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.60

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Journey Medical Corp's Company Valuation

Currency: USD Updated: 2026-05-18

The current valuation score of Journey Medical Corp is 8.02, ranking 32 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -17.05, which is -372.27% below the recent high of 46.43 and -104.13% above the recent low of -34.81.

Score

Industry at a Glance

Previous score

8.02

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/155

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-18

The current earnings forecast score of Journey Medical Corp is 8.00, ranking 57 out of 155 in the Pharmaceuticals industry. The average price target is 13.00, with a high of 16.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

13.500

Target Price

+113.27%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Journey Medical Corp

DERM

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-18

The current price momentum score of Journey Medical Corp is 9.14, ranking 22 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 7.03 and the support level at 5.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.13

Change

0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.381

Neutral

RSI(14)

65.843

Neutral

STOCH(KDJ)(9,3,3)

73.524

Buy

ATR(14)

0.410

High Vlolatility

CCI(14)

157.252

Buy

Williams %R

24.468

Buy

TRIX(12,20)

0.089

Sell

StochRSI(14)

90.448

Overbought

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

5.826

Buy

MA10

5.459

Buy

MA20

5.290

Buy

MA50

5.729

Buy

MA100

6.930

Sell

MA200

7.260

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-18

The current institutional shareholding score of Journey Medical Corp is 5.00, ranking 73 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 56.62%, representing a quarter-over-quarter increase of 93.34%. The largest institutional shareholder is Wasatch Global Investors, holding a total of 2.13M shares, representing 9.91% of shares outstanding, with 84.12% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fortress Biotech Inc

3.36M

Maraoui (Claude)

2.06M

+150.79%

Wasatch Global Investors Inc

Star Investors

1.32M

+0.77%

Tang Capital Management, LLC

1.85M

Opaleye Management Inc.

975.00K

+0.41%

J. Goldman & Co., L.P.

798.37K

BlackRock Institutional Trust Company, N.A.

655.76K

+14.66%

Alloush (Ramsey)

316.68K

+17.37%

Millennium Management LLC

457.81K

Risk Assessment

Currency: USD Updated: 2026-05-18

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Journey Medical Corp is 3.91, ranking 95 out of 155 in the Pharmaceuticals industry. The company's beta value is 1.07. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.